From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Supply@ME Interims – truly dismal and also just unbelievable: over to the FCA

By Tom Winnifrith | Friday 29 January 2021


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


We know from audited 2019 results released yesterday that as at this week, Supply@ME Capital (SYME) has still not signed one contract with a customer and has no cash with which to service any customers. Yes it has provided term sheets but that is not the same thing. I might well provide a term sheet to Cheryl Cole later today about a servicing proposition I have. But that, I am sad to say, would not be a binding contract! And without a contract or even a purchase order you simply, as a PLC, cannot book any revenues. Which brings us to today’s release of half calendar year 2020 results from the con that is Supply@ME Capital.

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Sunday »

Quiz

The ShareProphets Sunday Pub Quiz #272

 

AAU

Gold up Ariana down

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 12:19:07